TrialBone marrow transplantation2022

Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial.

Yingling Zu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.